436 related articles for article (PubMed ID: 9338484)
1. Potentiation of beta-lactams against Pseudomonas aeruginosa strains by Ro 48-1256, a bridged monobactam inhibitor of AmpC beta-lactamases.
Livermore DM; Chen HY
J Antimicrob Chemother; 1997 Sep; 40(3):335-43. PubMed ID: 9338484
[TBL] [Abstract][Full Text] [Related]
2. Effect of conalbumin on the activity of Syn 2190, a 1,5 dihydroxy-4-pyridon monobactam inhibitor of AmpC beta-lactamases.
Babini GS; Livermore DM
J Antimicrob Chemother; 2000 Jan; 45(1):105-9. PubMed ID: 10629020
[TBL] [Abstract][Full Text] [Related]
3. Mutation-driven β-lactam resistance mechanisms among contemporary ceftazidime-nonsusceptible Pseudomonas aeruginosa isolates from U.S. hospitals.
Castanheira M; Mills JC; Farrell DJ; Jones RN
Antimicrob Agents Chemother; 2014 Nov; 58(11):6844-50. PubMed ID: 25182652
[TBL] [Abstract][Full Text] [Related]
4. Carbapenemase-producing Pseudomonas aeruginosa in UK.
Woodford N; Palepou MF; Babini GS; Bates J; Livermore DM
Lancet; 1998 Aug; 352(9127):546-7. PubMed ID: 9716067
[No Abstract] [Full Text] [Related]
5. Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC.
Cabot G; Bruchmann S; Mulet X; Zamorano L; Moyà B; Juan C; Haussler S; Oliver A
Antimicrob Agents Chemother; 2014 Jun; 58(6):3091-9. PubMed ID: 24637685
[TBL] [Abstract][Full Text] [Related]
6. AmpG inactivation restores susceptibility of pan-beta-lactam-resistant Pseudomonas aeruginosa clinical strains.
Zamorano L; Reeve TM; Juan C; Moyá B; Cabot G; Vocadlo DJ; Mark BL; Oliver A
Antimicrob Agents Chemother; 2011 May; 55(5):1990-6. PubMed ID: 21357303
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial Effects of β-Lactams on Imipenem-Resistant Ceftazidime-Susceptible Pseudomonas aeruginosa.
Wi YM; Choi JY; Lee JY; Kang CI; Chung DR; Peck KR; Song JH; Ko KS
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373200
[TBL] [Abstract][Full Text] [Related]
8. Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates.
Humphries RM; Hindler JA; Wong-Beringer A; Miller SA
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993338
[TBL] [Abstract][Full Text] [Related]
9. WCK 4234, a novel diazabicyclooctane potentiating carbapenems against Enterobacteriaceae, Pseudomonas and Acinetobacter with class A, C and D β-lactamases.
Mushtaq S; Vickers A; Woodford N; Livermore DM
J Antimicrob Chemother; 2017 Jun; 72(6):1688-1695. PubMed ID: 28333319
[TBL] [Abstract][Full Text] [Related]
10. In-vitro activity of biapenem, compared with imipenem and meropenem, against Pseudomonas aeruginosa strains and mutants with known resistance mechanisms.
Chen HY; Livermore DM
J Antimicrob Chemother; 1994 May; 33(5):949-58. PubMed ID: 8089068
[TBL] [Abstract][Full Text] [Related]
11. Mutations in β-Lactamase AmpC Increase Resistance of Pseudomonas aeruginosa Isolates to Antipseudomonal Cephalosporins.
Berrazeg M; Jeannot K; Ntsogo Enguéné VY; Broutin I; Loeffert S; Fournier D; Plésiat P
Antimicrob Agents Chemother; 2015 Oct; 59(10):6248-55. PubMed ID: 26248364
[TBL] [Abstract][Full Text] [Related]
12. Phylogenetic analysis of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in piperacillin/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients.
Zamudio R; Hijazi K; Joshi C; Aitken E; Oggioni MR; Gould IM
Int J Antimicrob Agents; 2019 Jun; 53(6):774-780. PubMed ID: 30831233
[TBL] [Abstract][Full Text] [Related]
13. [Antibiotic susceptibility and occurrence of ESBL in Pseudomonas aeruginosa strains isolated from different clinical specimens].
Sacha PT; Jakoniuk P; Wieczorek P; Zalewska M; Leszczyńska K
Med Dosw Mikrobiol; 2004; 56(3):263-73. PubMed ID: 15773503
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates.
Buehrle DJ; Shields RK; Chen L; Hao B; Press EG; Alkrouk A; Potoski BA; Kreiswirth BN; Clancy CJ; Nguyen MH
Antimicrob Agents Chemother; 2016 May; 60(5):3227-31. PubMed ID: 26976862
[TBL] [Abstract][Full Text] [Related]
15. Antibiotic resistance and production of extended-spectrum beta-lactamases amongst Klebsiella spp. from intensive care units in Europe.
Livermore DM; Yuan M
J Antimicrob Chemother; 1996 Sep; 38(3):409-24. PubMed ID: 8889716
[TBL] [Abstract][Full Text] [Related]
16. Potentiation of ceftazidime by avibactam against β-lactam-resistant Pseudomonas aeruginosa in an in vitro infection model.
Sy SK; Zhuang L; Beaudoin ME; Kircher P; Tabosa MA; Cavalcanti NC; Grunwitz C; Pieper S; Schuck VJ; Nichols WW; Derendorf H
J Antimicrob Chemother; 2017 Apr; 72(4):1109-1117. PubMed ID: 28077672
[TBL] [Abstract][Full Text] [Related]
17. Comparative activity of meropenem against Pseudomonas aeruginosa strains with well-characterized resistance mechanisms.
Livermore DM; Yang YJ
J Antimicrob Chemother; 1989 Sep; 24 Suppl A():149-59. PubMed ID: 2553657
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study.
Cabot G; Ocampo-Sosa AA; Tubau F; Macia MD; Rodríguez C; Moya B; Zamorano L; Suárez C; Peña C; Martínez-Martínez L; Oliver A;
Antimicrob Agents Chemother; 2011 May; 55(5):1906-11. PubMed ID: 21357294
[TBL] [Abstract][Full Text] [Related]
19. Treatment of experimental pneumonia in rats caused by a PER-1 extended-spectrum beta-lactamase-producing strain of Pseudomonas aeruginosa.
Mimoz O; Elhelali N; Léotard S; Jacolot A; Laurent F; Samii K; Petitjean O; Nordmann P
J Antimicrob Chemother; 1999 Jul; 44(1):91-7. PubMed ID: 10459815
[TBL] [Abstract][Full Text] [Related]
20.
Goodlet KJ; Nicolau DP; Nailor MD
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
